Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation

References

• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Aug 25; 44(38):3720–3826. doi: 10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407–477. doi: 10.1093/eurheartj/ehz425
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367(9526):1903–12.
   PubMed Web of Science ®Google Scholar
• Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996 Apr 25;334(17):1084–9.
   PubMed Web of Science ®Google Scholar
• van Rein N, Heide-Jørgensen U, Lijfering WM, et al. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation. 2019 Feb 5;139(6):775–786.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016 Dec 22;375(25):2423–2434. doi: 10.1056/NEJMoa1611594
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017 Oct 19;377(16):1513–1524. doi: 10.1056/NEJMoa1708454
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509–1524. doi: 10.1056/NEJMoa1817083
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019 Oct 12;394(10206):1335–1343. doi: 10.1016/S0140-6736(19)31872-0
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019 Dec 7;40(46):3757–3767. doi: 10.1093/eurheartj/ehz732
   PubMed Web of Science ®Google Scholar
• Lopes RD, Hong H, Harskamp RE, et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol. 2020 May 1;5(5):582–589. doi: 10.1001/jamacardio.2019.6175
   PubMed Web of Science ®Google Scholar
• Galli M, Andreotti F, D’Amario D, et al. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):128–129. doi: 10.1093/ehjcvp/pvz030
   PubMed Web of Science ®Google Scholar
• Galli M, Andreotti F, Porto I, et al. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace. 2020 Apr 1;22(4):538–546. doi: 10.1093/europace/euz345
   PubMed Web of Science ®Google Scholar
• Capodanno D, Di Maio M, Greco A, et al. Safety and efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Am Heart Assoc. 2020 Aug 18;9(16):e017212.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001–2015. doi: 10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008 Jan;29(1):21–30. doi: 10.1093/eurheartj/ehm545
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045–1057. doi: 10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010 Oct 26;56(18):1456–1462. doi: 10.1016/j.jacc.2010.03.100
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692–694. doi: 10.1111/j.1538-7836.2005.01204.x
   PubMed Web of Science ®Google Scholar
• Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015 Nov;13(11):2119–2126. doi: 10.1111/jth.13140
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document. Circulation. 2018 Jun 12;137(24):2635–2650. doi: 10.1161/CIRCULATIONAHA.117.029289
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017 Mar 11;389(10073):1025–1034. doi: 10.1016/S0140-6736(17)30397-5
   PubMed Web of Science ®Google Scholar
• Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol. 2020 May 19;75(19):2414–2424. doi: 10.1016/j.jacc.2020.03.011
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019 Mar 5;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Agewall S, Andreotti F, et al. Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. Eur Heart J. 2022 Oct 7;43(37):3512–3527. doi: 10.1093/eurheartj/ehac294
   PubMed Web of Science ®Google Scholar
• de Veer A, Bennaghmouch N, Bor WL, et al. The WOEST 2 registry: a prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention. Neth Heart J. 2022 Jun;30(6):302–311.
   PubMed Web of Science ®Google Scholar
• Zeymer U, Toelg R, Wienbergen H, et al. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany. Herz. 2023 Mar;48(2):134–140.
   PubMed Web of Science ®Google Scholar
• Kitahara H, Yamashita D, Sato T, et al. Dual antithrombotic therapy with oral anticoagulant and P2Y12 inhibitors in patients with atrial fibrillation after percutaneous coronary intervention. J Cardiol. 2023 Sep;82(3):207–214. doi: 10.1016/j.jjcc.2023.06.002
   PubMed Web of Science ®Google Scholar
• Verlinden NJ, Coons JC, Iasella CJ, et al. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. J Cardiovasc Pharmacol Ther. 2017 Nov;22(6):546–551. doi: 10.1177/1074248417698042
   PubMed Web of Science ®Google Scholar
• Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019 May 14;40(19):1553–1562. doi: 10.1093/eurheartj/ehz059
   PubMed Web of Science ®Google Scholar
• Claessen BE, Henriques JP, Jaffer FA, et al. Stent thrombosis: a clinical perspective. JACC: Cardiovasc Interv. 2014 Oct;7(10):1081–92.
   PubMed Web of Science ®Google Scholar
• Rheude T, Koch T, Joner M, et al. Ten-year clinical outcomes of drug-eluting stents with different polymer coating strategies by degree of coronary calcification: a pooled analysis of the ISAR-TEST 4 and 5 randomised trials. EuroIntervention. 2023 Feb 20;18(14):1188–1196. doi: 10.4244/EIJ-D-22-00781
   PubMed Web of Science ®Google Scholar
• Amin AP, Wang TY, McCoy L, et al. Impact of bleeding on quality of life in patients on DAPT: insights from TRANSLATE-ACS. J Am Coll Cardiol. 2016 Jan 5;67(1):59–65. doi: 10.1016/j.jacc.2015.10.034
   PubMed Web of Science ®Google Scholar
• Sorrentino S, Sartori S, Baber U, et al. Bleeding risk, dual antiplatelet therapy cessation, and adverse events after percutaneous coronary intervention: the PARIS registry. Circ Cardiovasc Interv. 2020 Apr;13(4):e008226. doi: 10.1161/CIRCINTERVENTIONS.119.008226
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock S, Nikolsky E, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC: Cardiovasc Interv. 2011 Jun;4(6):654–664. doi: 10.1016/j.jcin.2011.02.011
   PubMed Web of Science ®Google Scholar
• Orme RC, Parker WAE, Thomas MR, et al. Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI). Circulation. 2018 Jun 21;138(13):1290–1300. doi: 10.1161/CIRCULATIONAHA.118.034790
   PubMed Web of Science ®Google Scholar
• Ortega-Paz L, Bor W, Franchi F, et al. P2Y(12) inhibition in patients requiring oral anticoagulation after percutaneous coronary intervention: the SWAP-AC-2 study. JACC: Cardiovasc Interv. 2024 Apr 1.
   Google Scholar
• Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol. 2020 Apr;17(4):242–257. doi: 10.1038/s41569-019-0314-y
   PubMed Web of Science ®Google Scholar